Other DPP-4 inhibitors, such as sitagliptin, have shown a neutral cardiovascular profile in separate studies like TECOS, suggesting that the heart failure risk may not be a class effect but rather specific to saxagliptin or certain patient populations. The gene discussed is DPP4; the disease is heart failure.